Overview

The management of non-Hodgkin lymphoma (NHL) is complex, and oncology pharmacists play a critical role in mastering the complex integration and toxicity of novel agents. Join leading experts in hematologic cancers for PTCE's 2026 Lymphoma Day of Education to review the pathophysiology of NHL subtypes, including aggressive diffuse large B-cell lymphoma and relapsing follicular lymphoma, and pharmacology of novel agents in both frontline and relapsed settings. Register early for these expert-led sessions that will examine clinical and operational strategies for the integration of CAR T-cell therapy and bispecific antibodies in NHL treatment.